KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Interest Expenses (2016 - 2023)

Supernus Pharmaceuticals (SUPN) has disclosed Interest Expenses for 13 consecutive years, with $910000.0 as the latest value for Q2 2023.

  • Quarterly Interest Expenses fell 49.72% to $910000.0 in Q2 2023 from the year-ago period, while the trailing twelve-month figure was $910000.0 through Mar 2024, down 86.28% year-over-year, with the annual reading at $2.4 million for FY2023, 65.84% down from the prior year.
  • Interest Expenses for Q2 2023 was $910000.0 at Supernus Pharmaceuticals, down from $1.5 million in the prior quarter.
  • The five-year high for Interest Expenses was $6.1 million in Q1 2021, with the low at $910000.0 in Q2 2023.
  • Average Interest Expenses over 5 years is $4.4 million, with a median of $5.7 million recorded in 2019.
  • The sharpest move saw Interest Expenses soared 718.69% in 2019, then tumbled 73.14% in 2022.
  • Over 5 years, Interest Expenses stood at $5.8 million in 2019, then rose by 5.52% to $6.1 million in 2020, then dropped by 2.66% to $5.9 million in 2021, then tumbled by 73.14% to $1.6 million in 2022, then tumbled by 42.91% to $910000.0 in 2023.
  • According to Business Quant data, Interest Expenses over the past three periods came in at $910000.0, $1.5 million, and $1.6 million for Q2 2023, Q1 2023, and Q4 2022 respectively.